A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of bimagrumab and tirzepatide, alone or together, on weight loss in adults who are obese or overweight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 252 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-10 · est. completion 2027-01

Where 12 sites · United States

What this study is testing ClinicalTrials.gov NCT06643728 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Treatments tested

Bimagrumab also known as LY3985863, BYM338, VER201 Drug

Administered SC
Tirzepatide also known as LY3298176 Drug

Administered SC
Bimagrumab Placebo Drug

Administered SC
Tirzepatide Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06643728 ↗